ReviewInternational journal of molecular sciences2025
From Molecules to Models: miRNAs and Advanced Human Platforms of Neurodegeneration and Repair in Multiple Sclerosis.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Beyond the potential role of microRNAs (miRNAs) as biomarkers, their participation in different biological and pathological processes observed in multiple sclerosis (MS) such as neuroinflammation, neurodegeneration and remyelination, makes them suitable candidates for therapeutic applications in neurorepair. Most studies addressing this reparative approach have been carried out using in vitro or in vivo model systems. However, functional differences between murine and human cells within the central nervous system (CNS) have been described, and certain mechanisms are distinctive in humans. The development of human models to investigate therapeutic interventions in neurological conditions including MS should be a priority to avoid failures. In this review, we provide a comprehensive summary of the advances in reparative therapeutic strategies for MS, including miRNAs and human models. We also discuss their benefits, the likely challenges they face and comment on possible mitigation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.